CLOs on the Move

Gift of Hope

www.giftofhope.org

 
Gift of Hope Organ & Tissue Donor Network is a not-for-profit organ procurement organization that coordinates organ and tissue donation and provides public education on donation in Illinois and northwest Indiana. As one of 58 OPOs that make up the nation’s donation system, we work with 180 hospitals and serve 12 million people in our donation service area. Since 1986, we have saved the lives of more than 23,000 organ transplant recipients and improved the lives of hundreds of thousands of tissue transplant recipients through our efforts.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

ACI Medical

ACI Medical is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Willow Crest Hospital

It is the vision of Willow Crest hospital to be the provider of choice for patients, family members, and referral sources. We shall strive to exceed expectations of our customers in the provision of high quality, cost effective services.

Midwest Heart Specialists-Advocate Medical Group

Midwest Heart Specialists-Advocate Medical Group is a Lombard, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LifeBrands

LifeBrands is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.